Results 101 to 110 of about 52,376 (272)

Management of Refractory Thymoma‐Associated Myasthenia Gravis With Sequential FcRn Antagonist and Complement Inhibition Combined With Resection of Pleural Dissemination

Neurology and Clinical Neuroscience, EarlyView.
ABSTRACT Myasthenia gravis (MG) associated with disseminated thymoma is often refractory to conventional treatments due to continuous autoantibody production. The optimal treatment strategy, particularly the combination of complement component 5 (C5) inhibitor, neonatal Fc receptor (FcRn) antagonist, and surgical resection in thymoma‐associated ...
Hiroyuki Takenaka, Madoka Iida, Yuki Fukami, Masahisa Katsuno   +3 more
wiley   +1 more source

Research on Exoskeleton Human-Machine Interaction for Walking Assistance in Myasthenia

Zhongguo yiliao qixie zazhi
To address the insufficient human-machine interaction adaptability in current lower-limb rehabilitation exoskeletons, this study proposes a lower-limb assistive exoskeleton featuring active actuation at the hip and knee joints and passive following at ...
Xinhai YIN, Huaixian LI, Jiawei HE, Lei YANG, Min ZHANG   +4 more
doaj   +1 more source

Efficacy Evaluation of Thymectomy in Myasthenia Patients [PDF]

Саратовский научно-медицинский журнал, 2009
The condition of 71 patients with myasthenia after thymectomy has been analyzed. Supervision has been carried out from 6 months till 9 years. Thymic hyperplasia has been marked at histological research of operational material in 46,5% of patients. Thymic
A.P. Reshetov, S.J. Pushkin, M.J. Belyakova, T.V. Romanova   +3 more
doaj  

Comparison of diagnostic tests in myasthenia gravis

, 1983
Results of 3 tests, intravenous edrophonium chloride, EMG, and acetylcholine receptor antibody testing, were compared in patients with generalised and ocular myasthenia gravis.
Nicholson, G. A., Griffiths, Lyn R., McLeod, J. G.   +2 more
core  

Current and emerging treatments for the management of myasthenia gravis

, 2011
Sivakumar SathasivamThe Walton Centre NHS Foundation Trust, Lower Lane, Liverpool, UKAbstract: Myasthenia gravis is an autoimmune neuromuscular disorder.
Sathasivam S, Sivakumar Sathasivam
core   +1 more source

Effectiveness and safety of efgartigimod in patients with anti‐NMDAR or anti‐LGI1 encephalitis and its 18F‐DPA714 PET imaging evaluation: A multicenter, single‐arm, prospective, observational real‐world study

Neuroprotection, EarlyView.
Abstract Background Efgartigimod disrupts the recycling of pathogenic IgG autoantibodies and may represent a candidate therapy for autoimmune encephalitis. This real‐world study evaluated the clinical efficacy, safety, and impact of efgartigimod on brain inflammation.
Huanyu Meng, Siqi Tu, Yifan Zhou, Ruinan Shen, Xiaoyu Chen, Zhaozhao Cheng, Limei Wang, Yan Wu, Jie Lu, Shengjun Wang, Yan Xu, Wanhui Lin, Sheng Chen   +12 more
wiley   +1 more source

Utility of the Predictive Summary Index for Comparison of Diagnostic Protocols in Myasthenia Gravis With Repetitive Nerve Stimulation and Concentric Needle Jitter

Brain and Behavior
Introduction As sensitivity of a test can be increased at the expense of specificity, a quality measure taking into account both parameters is desirable.
Peter Trillenberg, Daphne Schepers‐von Ohlen   +1 more
doaj   +1 more source

Coexistence of anti-synthetase syndrome, myasthenia and scleroderma: A scarce case report [PDF]

Romanian Journal of Rheumatology
Introduction. Polyautoimmunity refers to the phenomenon where an individual is affected by multiple autoimmune diseases simultaneously. This condition underscores the complexity of autoimmune disorders and their interconnected nature, often resulting ...
Sameh Sayhi, Arij Ezzouhour Yahyaoui, Nour Elhouda Guediche, Bilel Arfaoui, Faida Ajili, Nadia Ben Abdelhafidh   +5 more
doaj   +1 more source

Botulinum toxin use in patients with neurological disorders: A U.S.‐based claims database analysis

PM&R, EarlyView.
Abstract Background and Objective Real‐world evidence describing long‐term persistency with botulinum toxin (BoNT) therapy is limited. We assessed treatment patterns and persistency with BoNT in clinical practice over 2 years. Design Retrospective, longitudinal, claims database analysis. Setting Medical claims data from the Merative MarketScan database
David M. Simpson, Jonathan Bouchard, Simon Page, Seth Goldfarb, Atul T. Patel   +4 more
wiley   +1 more source

The Use of Parabulbar and Sub‐Tenon Injections to Correct Isolated Resistant Diplopia in Patients With Generalized Myasthenia Gravis: A Long Road to Clinically Meaningful Success

Clinical Case Reports
Parabulbar betamethasone provided rapid and durable relief of isolated, treatment‐resistant diplopia in seronegative myasthenia gravis after multiple systemic therapy failures, suggesting that targeted periocular corticosteroid delivery may be a steroid ...
M. Marchuk, V. Sanin, V. Mamilov, M. Zinchenko   +3 more
doaj   +1 more source